NYSE: BMY

Price$55.77 Change -0.59 %Change -1.05% Volume: 7,623,061 20 minute delay March 23, 2017

Bristol-Myers Squibb to Announce Results for First Quarter 2017 on April 27

03/10/2017

NEW YORK--(BUSINESS WIRE)-- Bristol-Myers Squibb Company (NYSE:BMY) will announce results for the first quarter of 2017 on Thursday, April 27, 2017. During a conference call at 10:30 a.m. EDT on April 27, company executives will review financial information and will address inquiries from investors and analysts.

Investors and the general public are invited to listen to a live webcast of the call at http://investor.bms.com or by dialing in the U.S. toll free 855-303-0072 or international 913-312-0976, confirmation code: 500711. Materials related to the call will be available at the same website prior to the conference call. A replay of the call will be available beginning at 1:30 p.m. EDT on April 27 through 1:30 p.m. EDT on, May 11, 2017. The replay will also be available through http://investor.bms.com or by dialing in the U.S. toll free 888-203-1112 or international 719-457-0820, confirmation code: 6160500.

About Bristol-Myers Squibb

Bristol-Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. For more information about Bristol-Myers Squibb, visit us at BMS.com or follow us on LinkedIn, Twitter, and YouTube.

Source: Bristol-Myers Squibb Company

Bristol-Myers Squibb Company

Media:

Ken Dominski, 609-252-5251

ken.dominski@bms.com

or

Lisa McCormick Lavery, 609-252-7602

lisa.mccormicklavery@bms.com

or

Investors:

John Elicker, 609-252-4611

john.elicker@bms.com

or

Tim Power, 609-252-7509

timothy.power@bms.com

or

Bill Szablewski, 609-252-5894

william.szablewski@bms.com

Materials on this website may contain information about the Company’s future plans and prospects that constitute forward-looking statements for purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Such forward-looking statements are based on current expectations and involve inherent risks and uncertainties, including factors that could delay, divert or change any of them, and could cause actual outcomes and results to differ materially from current expectations. No forward-looking statement can be guaranteed. Forward-looking statements contained on this website should be evaluated together with the many uncertainties that affect Bristol-Myers Squibb's business, particularly those identified in the cautionary factors discussion in the company’s most recent annual report on Form 10-K, quarterly reports on Form 10-Q and current reports on Form 8-K. These documents are available from the Securities and Exchange Commission, the Bristol-Myers Squibb website or from Bristol-Myers Squibb Investor Relations.

In addition, any information contained on this website was current as of the date presented and should not be relied upon as representing our estimates as of any subsequent date. While we may elect to update forward-looking statements at some point in the future, we specifically disclaim any obligation to do so, even if our estimates change, whether as a result of new information, future events or otherwise. Consequently, the company will not update the information contained on the website and investors should not rely upon the information as current or accurate after the presentation date. The website may also contain certain non-GAAP financial measures, adjusted to include certain costs, expenses, gains and losses and other specified items. Reconciliations of these non-GAAP financial measures to the most comparable GAAP measures for a particular quarterly period are available on the company’s website at www.bms.com.